AcquisitionOther
Morphic Holding, Inc. acquired Morphic to Improve Outcomes
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Morphic Holding, Inc. -> Morphic to Improve Outcomes · $57
Morphics lead program is a selective oral small molecule inhibitor of α4 b 7 integrin for the treatment of inflammatory bowel disease (IBD) that has the potential to improve outcomes and expand treatment options for patients.
Open source record (SEC) ↗